Full-Time
AI Engineer
Collate
11-50 employees
AI-driven documentation automation for life sciences
Compensation Overview
$150k - $350k/yr
San Francisco, CA, USA
In Person
 AI & Machine Learning (1) |
|---|
- Hands-on experience building and deploying ML/AI systems in production.
- Strong foundation in deploying search and retrieval systems and NLP applications.
- Ability to bridge research and engineering — from prototyping models to shipping them in user-facing products.
- Comfort working in an early-stage startup where ambiguity is high and ownership is expected.
- Motivation to apply AI to life sciences in a way that prioritizes reliability, safety, and impact.
- Prompt optimization, red-teaming, and improving robustness of LLMs for life-science NLP applications within Collate’s products.
- Build pipelines and infrastructure to deploy AI systems reliably, safely, and at scale.
- Collaborate with product, design, and engineering teams to translate user needs into AI-driven features.
- Develop evaluation frameworks to ensure models are accurate, fair, and trustworthy in real-world life science settings.
- Experiment rapidly, while balancing iteration speed with the rigor required for high-stakes applications.
- Create tools and workflows that make AI development more efficient across the team.
Collate provides an AI-powered platform that automates the creation and management of documentation for drug development, medical devices, and diagnostics. It works by generating, organizing, and governing regulatory and quality documents while offering data discovery and governance tools to ensure high-quality data assets. It distinguishes itself by offering an end-to-end, life-sciences–focused solution that covers drug, device, and diagnostic workflows in one platform, reducing manual work and speeding up approvals. Its goal is to shorten development and regulatory timelines so researchers can focus on discovery and bring life-saving innovations to patients faster.
Company Size
11-50
Company Stage
Seed
Total Funding
$30M
Headquarters
San Francisco, California
Founded
2025
Simplify's Take
What believers are saying
- Pfizer's 20% manufacturing throughput gains validate AI documentation automation market demand.[5]
- UCSF ARPA-H funding accelerates open-source drug development, creating IND filing opportunities.[5]
- Moderna's AWS AI integration demonstrates enterprise adoption of automated quality control workflows.[5]
What critics are saying
- Pfizer's proprietary generative AI platform directly competes in manufacturing documentation automation.[5]
- FDA's DARRTS system with AI language models bypasses Collate's regulatory submission tools.[7]
- Open-source models from UCSF and Open Molecular Software Foundation commoditize documentation automation.[5]
What makes Collate unique
- Acquired MantleBio to deepen AI capabilities across entire drug development lifecycle.[1]
- Generative AI automates regulatory submissions, clinical trials, and quality management workflows.[2][3]
- AI Studio and SDK enable custom agents without external infrastructure dependencies.[8]
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Flexible Work Hours
Professional Development Budget
Company News
Biotech startup Collate, founded by Surbhi Sarna, has secured a $30 million seed fund to automate paperwork in the life sciences industry using AI. The funding round was led by Redpoint, with participation from First Round, Conviction Partners, and YC, valuing Collate at over $100 million. Collate aims to streamline documentation for diagnostic, medical device, and drug development companies, enhancing R&D and reducing time to market. Co-founders Nate Smith and Jigish Patel bring additional expertise.
Y Combinator's Surbhi Sarna has raised $30 million for Collate, a startup aiming to automate the tedious parts of running a life sciences business using AI.